What question did this study set out to answer?

To determine whether replacing two cycles of intensive conventional chemotherapy with blinatumomab increases 4-year event-free survival by at least 10 percentage points in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia.

September 17, 2026New England Journal of Medicine

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia

View Full Paper

Ask AI

Bookmark

Authors

MSMartin SchrappeKiel University FLFranco LocatelliUniversità Cattolica del Sacro Cuore MVMaria Grazia ValsecchiUniversity of Milano-Bicocca

Discussion

Member takes

Overview

Randomized trial demonstrates superior event-free survival with blinatumomab in pediatric high-risk acute lymphoblastic leukemia, indicating immunotherapy can replace toxic chemotherapy cycles.

Key Points

To determine whether replacing two cycles of intensive conventional chemotherapy with blinatumomab increases 4-year event-free survival by at least 10 percentage points in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia.
Randomized trial allocating children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (N=709) in a 1:1 ratio after consolidation to receive either two cycles of blinatumomab (n=358) or two cycles of intensive chemotherapy (n=351).
Evaluated primary endpoint of event-free survival—defined as time to protocol resistance, relapse, second cancer, or death from any cause—at a planned interim analysis with a median follow-up of 2.9 years.
Estimated 4-year event-free survival reached 83.0% (95% CI, 77.4 to 87.4) in the blinatumomab arm compared to 70.3% (95% CI, 63.8 to 75.9) in the chemotherapy control arm (HR 0.51; 95% CI, 0.35 to 0.73; P=0.0002).
Treatment-related infections occurred in 23.9% of blinatumomab-treated patients versus 69.4% of chemotherapy recipients (P<0.001), and life-threatening adverse events occurred in 0.5% versus 4.7%.
Neurotoxic adverse events were higher in the blinatumomab group (12.0% vs. 3.2%, P<0.001), while grade 2 or higher cytokine release syndrome affected 1.1% of patients receiving blinatumomab.

Cite This Study

Schrappe et al. (2026) studied this question.

synapsesocial.com/papers/6aabafda20b725bb9d86f000 https://doi.org/10.1056/nejmoa2604166

View Full Paper

Ask AI

Bookmark

September 17, 2026New England Journal of Medicine

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia

View Full Paper

Ask AI

Bookmark

Authors

MSMartin SchrappeKiel University FLFranco LocatelliUniversità Cattolica del Sacro Cuore MVMaria Grazia ValsecchiUniversity of Milano-Bicocca

Discussion

Member takes

Overview

Randomized trial demonstrates superior event-free survival with blinatumomab in pediatric high-risk acute lymphoblastic leukemia, indicating immunotherapy can replace toxic chemotherapy cycles.

Key Points

To determine whether replacing two cycles of intensive conventional chemotherapy with blinatumomab increases 4-year event-free survival by at least 10 percentage points in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia.
Randomized trial allocating children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (N=709) in a 1:1 ratio after consolidation to receive either two cycles of blinatumomab (n=358) or two cycles of intensive chemotherapy (n=351).
Evaluated primary endpoint of event-free survival—defined as time to protocol resistance, relapse, second cancer, or death from any cause—at a planned interim analysis with a median follow-up of 2.9 years.
Estimated 4-year event-free survival reached 83.0% (95% CI, 77.4 to 87.4) in the blinatumomab arm compared to 70.3% (95% CI, 63.8 to 75.9) in the chemotherapy control arm (HR 0.51; 95% CI, 0.35 to 0.73; P=0.0002).
Treatment-related infections occurred in 23.9% of blinatumomab-treated patients versus 69.4% of chemotherapy recipients (P<0.001), and life-threatening adverse events occurred in 0.5% versus 4.7%.
Neurotoxic adverse events were higher in the blinatumomab group (12.0% vs. 3.2%, P<0.001), while grade 2 or higher cytokine release syndrome affected 1.1% of patients receiving blinatumomab.

Cite This Study

Schrappe et al. (2026) studied this question.

synapsesocial.com/papers/6aabafda20b725bb9d86f000 https://doi.org/10.1056/nejmoa2604166

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark